Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Beccari MV, Meaney CJ. Core Evid. 2017;12:11–24.
On page 12, in the “Core evidence clinical impact summary for patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate in the treatment of hyperkalemia” section, the “Implications” text for “Patient-oriented evidence” was incorrectly listed as: “Iloperidone was more effective than placebo and similar to haloperidol, risperidone, and ziprasidone in several psychometric scales and in symptoms assessment.”
The correct details are: “Patiromer and ZS-9 allowed for the initiation, titration, and maintenance of renin-angiotensinaldosterone system inhibitor therapy in patient populations that derive significant benefit, such as chronic kidney disease and heart failure. The ability of SPS to maintain normokalemia during renin-angiotensin-aldosterone system inhibitor continuation or dose titration is unclear.”
Read the original article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]